emphasized adaptation towards clinical applications in treatment of various disease conditions [16] [17] [18] . The use of RNAi technology permits high specificity targeting of key genes and a significant silencing upon successful delivery [19] . This review will outline recent developments of RNAi based treatments for ischemic and traumatic injury to the CNS and emphasize non-viral delivery strategies. DOI 10.1515DOI 10. /rnan-2016 Received May 12, 2016; accepted June 22, 2016 Abstract: Neuronal axons damaged by traumatic injury are unable to spontaneously regenerate in the mammalian adult central nervous system (CNS), causing permanent motor, sensory, and cognitive deficits. Regenerative failure in the adult CNS results from a complex pathology presenting multiple barriers, both the presence of growth inhibitors in the extrinsic microenvironment and intrinsic deficiencies in neuronal biochemistry, to axonal regeneration and functional recovery. There are many strategies for axonal regeneration after CNS injury including antagonism of growth-inhibitory molecules and their receptors, manipulation of cyclic nucleotide levels, and delivery of growth-promoting stimuli through cell transplantation and neurotrophic factor delivery. While all of these approaches have achieved varying degrees of improvement in plasticity, regeneration, and function, there is no clinically effective therapy for CNS injury. RNA interference technology offers strategies for improving regeneration by overcoming the aspects of the injured CNS environment that inhibit neurite growth. This occurs through the knockdown of growth-inhibitory molecules and their receptors. In this review, we discuss the current state of RNAi strategies for the treatment of CNS injury based on non-viral vector mediated delivery.
Introduction
Central nervous system (CNS) damage resulting from traumatic or ischemic injury is a pathology that is poorly addressed by current therapeutic strategies. According to the National Spinal Cord Injury Statistical Center, spinal cord injury (SCI) within North America alone accounts for 300,000 patients living with persistent effects with another 11,000 new cases annually [1] . Injuries to the brain provide an even greater population of affected patients with traumatic brain injury (TBI) presenting at least 1.7 million new cases annually in the United States and ischemic stroke accounting for 5 million patients worldwide who live with persistent symptoms [2, 3] . There is no clinically approved treatment to restore tissue function despite millions of individuals who continue to live with persistent symptoms and suffer from a reduced quality of life [2, [3] [4] [5] . Following injury, regeneration in the adult CNS is limited by reactive astrogliosis and exposure of myelin-associated inhibitory molecules that activate signaling pathways inhibiting axonal growth, [6] [7] [8] [9] [10] [11] , as well as decreased levels of signaling molecules such as cyclic Adenosine monophosphate (cAMP) [1, [12] [13] [14] .
RNA interference (RNAi) technology has grown steadily since its advent in the 90s when Andrew Fire and Craig Mello presented successful sequence-specific inhibition of gene expression through interaction of injected long double stranded RNA with endogenous mRNA [15] . In recent years RNAi technology has
RNAi mechanism
The process of RNAi is initiated both endogenously and exogenously. Figure 1 summarizes the different modes for the processing of endogenous miRNAs and exogenous shRNAs or siRNAs within a cell. The natural endogenous mechanism relies upon short RNA segments referred to as micro-RNAs (miRNAs) [15, 20, 21] . These miRNAs are approximately 22 nucleotides long and reach their final active form following trimming by enzymatic complexes. The miRNA molecule is initially transcribed as a long primary transcript referred to as a pri-miRNA. This primiRNA transcript is then cleaved within the nucleus by the RNase Drosha into a shorter hairpin structure or pre-miRNA. The transporter protein Exportin-5 mediates transfer of the pre-miRNA to the cytoplasm where the RNase Dicer processes the pre-miRNA to its active miRNA segments [22] [23] [24] . The active miRNA segments trigger degradation or inhibit translation of target mRNAs to which they bind with full or partial complementarity, respectively [25] . In an attempt to adapt these mechanisms, researchers have developed techniques using exogenously applied small interfering RNAs (siRNAs), short-hairpin RNAs (shRNAs), and artificial miRNAs [26] . Artificially produced pri-miRNAs are processed in the same way as endogenous counterparts, whereas both the long siRNA molecules and shRNAs are processed similarly to pre-miRNAs. The siRNA molecules (20-25 base pairs) resemble final stage miRNAs in structure and bypass processing by both Drosha and Dicer prior to incorporation to the RNA-induced silencing complex (RISC). In both siRNAs and fully complementary miRNAs, the sense strand is discarded and the antisense strand is used for recognition and subsequent cleavage of complementary mRNA molecules, effectively halting their translation [26] .
Several challenges impede the development of clinically relevant treatments. For successful RNAi The diagram summarizes the different modes for processing of endogenous miRNAs and exogenous shRNAs or siRNAs in a cell. Endogenous miRNAs begin as long primary RNA (Pri-miRNA) transcripts, which are consecutively processed by the RNases Drosha to a 70-nucleotide stem-loop structure called a pre-miRNA, which is further cleaved by Dicer to form miRNA/miRNA duplexes. Active miRNAs can then lower protein expression through either full or partial complementarity with an mRNA target. The exogenous shRNA and siRNAs are designed to act through full complementarity with an mRNA target. Delivered siRNAs bypass processing by both Drosha and Dicer, whereas the hairpin shaped shRNAs still require processing by Dicer to liberate the siRNA duplex. therapy, the main challenge is successful delivery to the target site. Naked RNAs are readily degraded by nucleases in the body and have difficulty reaching the desired tissues or organs because they are distributed throughout the body. The RNAs, especially siRNAs, show short circulation time due to their size (below 10nm) and are readily excreted through renal filtration [17] . Even when they reach to the desired site, naked RNAs cannot pass the cell membrane due to their negative charge. Furthermore, there are some unintended toxic effects caused when delivered siRNAs interact with endogenous miRNA pathways or downregulate off-target genes [18, 26] . As a result, unmodified RNAs typically have a low rate of success [19, 27] .
CNS Barriers
Delivery of nucleic acids to the CNS is limited by the blood brain barrier (BBB), a key limiting factor for success of potential therapies [12, 29] . CNS homeostasis is maintained by a set of specialized barriers that control the passage and retention of nutrients, proteins, and other small molecules within specialized compartments. Since cerebral spinal fluid (CSF) is able to exchange substances directly with the tissues of the CNS, the passage of substances from blood must be strictly controlled to maintain homeostasis. For this purpose, the BBB guards against molecules uncontrollably penetrating the vasculature of the CNS [29] [30] [31] . In the CNS, the microvasculature walls are formed by a single layer of endothelial cells with tight junctions that render the wall impermeable to all except a select group of molecules [32] . Small water soluble and lipid soluble molecules such as oxygen, carbon dioxide, and steroid hormones, can easily cross the membrane, whereas all other metabolic products such as glucose must be actively transported [29] . Instead of trans-cellular transportation, charged molecules must be selectively transported through the cell to gain entry to the CNS compartment. The tight endothelial barrier is accompanied by astrocytes and pericytes, which form a secondary barrier surrounding a majority of the capillaries, further restricting molecular passage [29, 33] (Figure 2 ). However, the BBB is not ubiquitous and specific secretory or sensory zones such as the olfactory bulb do not have the BBB. Intra-nasal delivery is therefore an attractive route of delivery to the CNS [31] . In addition to the BBB, the blood-cerebrospinal fluid barrier (BCFB), formed by networks of capillaries, acts as a filtration system for blood plasma, preventing direct exchange of molecules with the CNS tissue. Though passage through the BCFB can allow therapeutic molecules access to the brain, the distribution of therapeutic molecules passing through the BBB is far higher, and as a result is the method of choice when seeking entry to the CNS [29] .
Non-Viral Vector Delivery
While several viral vectors have demonstrated efficient gene knockdown, they often lack specificity and evoke immune reactions and inflammation [17, 34] . To overcome these concerns, non-viral strategies such as naked RNAs, lipid- [35] [36] [37] , peptide- [38] , and polymer-based [27, [38] [39] [40] carriers for RNAi therapeutics are undergoing development with improved safety and reduced immunogenicity. Several classes of lipids including cationic [40, 41] , anionic [42] , and uncharged [41] are commonly used as carriers for the delivery of nucleic acid therapeutics [34] . The polymers utilized for delivery of nucleic acids can be charged or uncharged including poly (caprolactone) [26] , poly (ethylene glycol) [38] , and polyethylenimine (PEI) [27, 38] . Table 1 shows an overview of non-viral mediated RNAi strategies discussed in this review.
Chemical Modification of siRNAs
Application of naked siRNAs in vivo is limited by instability and low membrane penetration ability of the siRNA molecule. These obstructions to successful siRNA therapeutic application have encouraged the development of chemically modified siRNAs for increasing siRNA stability and maintaining silencing capability [44, 45] . Chemical modifications to the vulnerable end groups represent one approach to combat insufficiencies in both stability and penetration of siRNA constructs. Addition of an O-Methyl or a fluoro group to the 2' carbon of the sugar moiety in the siRNA can effectively stabilize the siRNA molecule in plasma [5, 44, 45] . The replacement of the 3' phosphodiester linkage with a phosphorothioate has proven effective for stabilization of siRNAs in vivo [5, 45] . In a study reported by Querbes et al., siRNAs were modified with deoxythymidine overhangs containing 2'-O-Methyl substitutions as well as phosphorothioate linkages for stabilization against nuclease activity. Delivery of these modified siRNAs was performed via convection enhanced delivery through an infusion cannula directed to the corpus callosum. The infusion delivery resulted in oligodendrocyte specific knockdown of 2′,3′-cyclic nucleotide 3′-phosphodiesterase (CNPase) at the injection site and areas distant of the injection site [5] . Nakajima et al. demonstrated effective neuron-specific knockdown of cyclophilin-B and GAPDH following an intracerebroventricular injection of chemically modified Accell siRNAs from Dharmacon in rats. In addition, they did not observe toxicity or neuro-inflammation associated with the successful knockdown results [44] . Though these studies demonstrate encouraging knockdown results and a positive outlook, Querbes et al did not characterize the immune response observed following long term siRNA infusion. Nakajima et al reported that the transfection only occurred in non-dividing neuron cells, but were not able to discover the reason for this phenomena. Before these strategies can progress towards clinical application a more in depth understanding of the mechanism of action and off target effects is required. Even though chemical modification can be an extremely effective technique, its use is limited by concerns of inhibiting the therapeutic efficacy through proximity to the active region of the siRNA, and generation of harmful metabolites upon degradation [33, 45] . Chemical modification also does not completely protect siRNAs from degradation by nucleases in vivo, and therefore strategies for encapsulating and targeting siRNAs have become increasingly interesting.
Lipid-Based Vector Delivery
For delivery of these nucleic acid molecules, cationic lipids are often chosen because their charge allows them to electrostatically bind to negatively charged nucleic acid molecules [45, 46] . Hassini et al tested the use of various non-viral vectors and formulation methods in RNAi applications in mouse brains in vivo. They used polyethyleneimine (PEI)-based polyplexes and JetSI™ (a mixture of cationic lipids)-based lipoplexes to deliver the luciferase gene and siRNA directed against the luciferase gene. They reported that linear PEI did not knockdown the luciferase gene within the dose range tested (<0.5 pmol) even though PEI delivered nucleic acids to cells efficiently. They tested various combinations of cationic lipids and reported that the combination of JetSI TM with fusogenic lipid DOPE showed the best knockdown efficiency (78+/-6 % knockdown at a 24 hrs post-transfection with 0.2 pmol siRNA. [35] . Recently, Afonin et al. showed promise in stabilizing siRNAs using RNA-DNA hybrids associated with bolaamphiphile cationic carriers. The release of functional double stranded siRNAs was controlled by separately hybridizing the sense and anti-sense strands. When both hybrids are present in the cell, the DNA strands re-associate and release the siRNA. This technology offers greater control for targeting specificity without negative effect upon the silencing capability of the siRNAs [47] . Despite achieving the desired level of transfection efficiency, delivery of nucleic acids via cationic lipids is still associated with significant toxicity, particularly in neurons [48, 49] . An interesting solution within the realm of lipid delivery involves the usage of naturally occurring exosomes [50, 51] . Exosomes are nanoscale vesicles that are secreted by various cell types and are capable of transporting endogenous miRNAs [52, 53] . Alvarez-Everti et al. isolated exosomes from bone marrow stem cells obtained from C57BL/6 mice. The exosomes were modified with a targeting peptide, rabies viral glycoprotein (RVG) that is specific to the CNS. The results of this study following tail vein injection in rats showed minimal cytotoxicity in neural cells with neuron-specific knockdown by the encapsulated GAPDH siRNAs. This technique offers promise for the targeting of CNS disorders including both traumatic and ischemic injuries if the correct targeting moieties are selected [51] .
Polymer-Based Vector Delivery
Though lipid-based strategies are useful, synthetic and natural polymers have shown promising application with RNAi with more versatile methods including nanoparticles, polymeric micelles, or dendrimers [54] [55] [56] .
Shu et al reported that natural polymeric nanoparticles using bacteriophage phi29 derived packaging RNA (pRNA) stabilized siRNAs for successful knockdown following systemic administration [17] . These pRNA nanoparticles are capable of delivering multiple siRNAs with different therapeutic targets and exhibit minimal cytotoxicity [57, 58] . The size of these nanoparticles ranges from 20-40 nm [17] , which is within the range of 10 to 100nm that is considered as optimal particle size range for non-viral vectors [59, 60] . In a study by Abdelmawla et al., pRNA nanoparticles were modified by folate conjugation for targeting folate receptor positive (FR+) tumors. The particles showed selective uptake in the FR+ cells with minimal activation of inflammatory response and negligible uptake into the liver, spleen, and kidneys [61] . The ability of pRNA nanoparticles to avoid immune activation and clearance, coupled with their ability to target specific cells through small molecule conjugation, would allow for adaptation to CNS delivery through the addition of molecules targeting the BBB.
Polyethylenimine (PEI) is a polycationic polymer that has shown success in gene delivery to the CNS [62] [63] [64] . Though it has shown successful application in several diseases, significant cytotoxicity is often a concern when higher doses are required to elicit an effect [65] . This is the limitation of PEI as a gene delivery carrier in clinical CNS application. In a study by Gwak et al a cationic amphiphilic co-polymer, poly(lactide-co-glycolide)-graftpolyethylenimine (PgP) was developed and successfully applied both in vitro and in vivo. This PgP polymer has been developed for combinatorial delivery of drugs and nucleic acids for axon regeneration after CNS injury. They reported that PgP can efficiently knockdown (~65%) GFP by transfecting PgP/GFP siRNA polyplexes in B35 cells in media containing 10% serum, which was similar to that obtained with RNAiMAX/GFP siRNA (~70 %). [66] Another polymer that has been applied towards RNAi technology following modification with amphiphilic and cationic molecules is cyclodextrin (CD) [66] [67] [68] [69] . O'Mahony et al. sought to create a neuron-specific delivery system for siRNA by modifying CDs through "click" chemistry. This strategy optimizes a non-viral delivery system using an 'ABCD' concept [70] with the four portions being the nucleic acid cargo, the portion that complexes the nucleic acid, a stabilizing portion such as polyethylene glycol (PEG), and a targeting moiety. O'Mahony et al. reported that the addition of PEG chains to the CD molecules increased stability of the molecule, but at the same time reduced the siRNA delivery through reducing interaction with the cell membrane. The use of PEG modification does not always result in poor activity of RNAi technology as is shown by Kanazanwa et al. when delivering polyethylene glycolpolycaprolactone (PEG-PCL) nanoparticles modified with HIV-1 Tat peptide. The delivery of these particles was accomplished through intranasal delivery to eight-week old rats, the results demonstrated successful delivery of siRNAs specifically to the CNS tissue with limited toxicity [31] . This technique has the added benefit of improving the efficacy of the non-invasive siRNA delivery.
Another polymeric vehicle that has shown promise as a vehicle for mediating RNAi is polyamidoamine (PAMAM) dendrimer grafted with L-arginine [71] . Il-Doo Kim et al. reported that PAMAM-Arg modified with an ester linkage (e-PAM-Arg) was capable of binding and delivering siRNAs against high mobility group box 1 (HMGB1). In the animal models for this study the e-PAM-Arg/siRNA complex was injected stereotaxically into the rat's cortex. The e-PAMArg/siRNA complexes were able to achieve 40% siRNA transfection in neuron cells following injection to the rat brains. In addition, it was found that successful siRNAmediated HMGB1 knockdown inhibited neuronal death and also decreased infarct volume in post-ischemic rat brains [71] . These positive results can bolster the confidence in a successful future treatment for ischemic injuries in the CNS.
In a study reported by Fukuda et al, successful RNAi in the treatment of rat cortical impact TBI model was accomplished through knockdown of Aquaporin-4 (AQP4) by local injection of siRNAs complexed with the commercially available non-liposomal cationic amphiphilic Interferin (Polypus Transfection) [72] . In addition to successful AQP4 knockdown, this study also reported decreased astrogliosis at early time points, decreased edema, increased microglia activation, and increased neuron cell survival compared to a non-specific siGLO control [72] . They report that significant functional recovery was achieved for up to 3 days post-injury compared to siGLO as a control [67] . In a study by Chelluboina et al., Jet-PEI nanoparticle vectors complexed with plasmids expressing shRNAs against metalloproteinase 12 (MMP-12) were delivered intravenously to treat cerebral ischemia [4] . The shRNA against metalloproteinase-12 (MMP-12) was encoded in plasmid vectors and expressed through strong Pol III promoters including U6 and H1, which exhibit intense levels of expression [73] [74] [75] [76] . The study highlighted MMP-12 as a potential therapeutic target for ischemia and demonstrated that shRNA in plasmid vectors could effectively knockdown MMP-12 when intravenously administered [4] . Though capable of significant knockdown, shRNA delivery can be associated with a higher cell toxicity that has been attributed to intense expression by successfully transfected cells [26, 76] .
To address the challenge of non-specific uptake and provide targeting capability, Park et al conjugated branched PEI with tetanus toxin peptide (Tet1), which has high affinity for dorsal root ganglion and primary motor neurons. These Tet1-modified nanoparticles showed successful targeting of differentiated PC-12 neuron cells, primary dorsal root ganglion cells, and primary neurons in mixed culture with primary astrocytes. The Tet1 modified PEI nanoparticles exhibit promise as a delivery vector capable of targeting the CNS in vivo proven by their specific binding to neuron cells [38] .
Conclusions and Outlook
Emerging RNAi technologies applied to CNS treatment require extensive research before they can undergo successful clinical application. In this mini-review, we cover recent progress made in RNAi technology based on non-viral gene carriers that are classified in chemical modification of RNA, lipid-based, and polymer-based carries used in CNS injury. RNAi therapeutic technologies have been developed with enhanced knockdown of target gene expression, but still need to reduce offtarget effects, immune response, and cytotoxicity. Despite the improvements necessary for the acceptance of these technologies as established clinical therapies, the progress of these technologies to this point offers promise that future patients with these disorders have access to therapies capable of restoring the function of their cognitive and motor skills towards their original capabilities.
